Your browser doesn't support javascript.
loading
BRD4 Inhibition as a Strategy to Prolong the Response to Standard of Care in Estrogen Receptor-Positive Breast Cancer.
Elshazly, Ahmed M; Sinanian, Melanie M; Neely, Victoria; Chakraborty, Eesha; Alshehri, Muruj A; McGrath, Michael K; Harada, Hisashi; Schoenlein, Patricia V; Gewirtz, David A.
Affiliation
  • Elshazly AM; Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Sinanian MM; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Neely V; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33516, Egypt.
  • Chakraborty E; Departments of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Alshehri MA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • McGrath MK; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Harada H; Philips Institute for Oral Health Research, School of Dentistry, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Schoenlein PV; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA.
  • Gewirtz DA; C. Kenneth and Dianne Wright Center for Clinical and Translational Research, Virginia Commonwealth University, Richmond, VA 23298, USA.
Cancers (Basel) ; 15(16)2023 Aug 11.
Article in En | MEDLINE | ID: mdl-37627092

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2023 Document type: Article Affiliation country: United States Country of publication: Switzerland

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Cancers (Basel) Year: 2023 Document type: Article Affiliation country: United States Country of publication: Switzerland